Figure 1 4.1.1 Cardiovascular outcomes in SGLT2 inhibitors: safety studies The EMPA-REG OUTCOME trial, which included 7020 patients with T2DM, was the first to demonstrate the cardiovascular protective effects of empagliflozin ( Subsequent trials, such as CANVAS and DECLARE-TIMI 58, have further confirmed the cardiovascular benefits of SGLT-2 inhibitors
Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J
The Assessment Process Before starting any program, it is essential to be honest about your medical history
The goal of maintenance is straightforward: find the dose that helps you maintain appetite control and fullness while keeping your weight stable
It is very similar to semaglutide, but has shown more weight loss in studies